广东赛烽医药科技

Guangdong Saifeng Pharmaceutical Technology is a biotechnology company dedicated to the development of innovative protein degradation therapies. Based in Guangzhou, China, the company utilizes its proprietary PROTAC platform to design small molecules that hijack the body's natural protein disposal system to eliminate disease-causing proteins. Their research primarily targets high-value, "undruggable" proteins associated with cancer and inflammatory conditions. Saifeng Pharma is led by an experienced scientific team and has successfully raised significant capital from top-tier investors to advance its early-stage pipeline. The company's lead programs are currently in the pre-clinical stage, focusing on hematological malignancies and solid tumors.